Study revises thinking on genes and breast cancer risk January 22, 2021 -- Women who have mutations associated with breast cancer are not necessarily at higher risk as previously thought, according to a large review of epidemiology studies published January 20 in the New England Journal of Medicine.
Qiagen plans FDA resubmission of coronavirus rapid antigen test January 21, 2021 -- Qiagen is planning a first-quarter resubmission of its QIAreach rapid antigen test to the U.S. Food and Drug Administration (FDA). In separate news, the company said that its molecular diagnostics are effective for detection of the various known strains of the coronavirus.
Hexapod personal protective booths cut testing costs for COVID-19 January 19, 2021 -- As the COVID-19 pandemic continues to evolve, hospitals and labs have had to get creative, overcome hurdles, and adapt their practices to perform safer COVID-19 testing. One solution is the Hexapod, which is a personal protective booth that allows healthcare providers to undertake swab testing without physically contacting patients. Discuss
Ortho files for IPO to sell 70M shares January 19, 2021 -- Ortho Clinical Diagnostics has filed for an initial public offering (IPO) that aims to sell 70 million shares at a price between $20 and $23 per share. The company's shares will be traded on the Nasdaq stock exchange under the symbol "OCDX."
Quest wins CDC contract to sequence COVID-19 gene variants January 19, 2021 -- Quest Diagnostics has received a contract from the U.S. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing for a project aimed at identifying new mutations and patterns of transmission of SARS-CoV-2.
Exact Sciences nabs license for TARDIS January 16, 2021 -- Exact Sciences has acquired a worldwide exclusive license for targeted digital sequencing (TARDIS) technology from the Translational Genomics Research Institute.
ADA lowers optimal blood sugar levels for kids January 15, 2021 -- The American Diabetes Association (ADA) has issued new guidelines for optimal A1C levels in pediatric patients with type 1 diabetes, lowering them to 7% hemoglobin A1C levels, instead of 7.5%, as per their 2019 guidelines.